| Dabigatran versus warfarin in patients with atrial fibrillation SJ Connolly, MD Ezekowitz, S Yusuf, J Eikelboom, J Oldgren, A Parekh, ... New England journal of medicine 361 (12), 1139-1151, 2009 | 14248 | 2009 |
| 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS P Kirchhof, S Benussi, D Kotecha, A Ahlsson, D Atar, B Casadei, ... Polish Heart Journal (Kardiologia Polska) 74 (12), 1359-1469, 2016 | 12254 | 2016 |
| 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The … G Hindricks, T Potpara, N Dagres, E Arbelo, JJ Bax, ... European heart journal 42 (5), 373-498, 2021 | 8726 | 2021 |
| The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation J Steffel, P Verhamme, TS Potpara, P Albaladejo, M Antz, L Desteghe, ... European heart journal 39 (16), 1330-1393, 2018 | 3142 | 2018 |
| Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term … JW Eikelboom, L Wallentin, SJ Connolly, M Ezekowitz, JS Healey, ... Circulation 123 (21), 2363-2372, 2011 | 1536 | 2011 |
| Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation H Heidbuchel, P Verhamme, M Alings, M Antz, HC Diener, W Hacke, ... Ep Europace 17 (10), 1467-1507, 2015 | 1466 | 2015 |
| Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation CP Cannon, DL Bhatt, J Oldgren, GYH Lip, SG Ellis, T Kimura, M Maeng, ... New England Journal of Medicine 377 (16), 1513-1524, 2017 | 1431 | 2017 |
| Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis … L Wallentin, S Yusuf, MD Ezekowitz, M Alings, M Flather, MG Franzosi, ... The Lancet 376 (9745), 975-983, 2010 | 1295 | 2010 |
| European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation H Heidbuchel, P Verhamme, M Alings, M Antz, W Hacke, J Oldgren, ... Europace 15 (5), 625-651, 2013 | 1262 | 2013 |
| Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial J Oldgren, A Budaj, CB Granger, Y Khder, J Roberts, A Siegbahn, ... European heart journal 32 (22), 2781-2789, 2011 | 731 | 2011 |
| Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion R Nagarakanti, MD Ezekowitz, J Oldgren, S Yang, M Chernick, TH Aikens, ... Circulation 123 (2), 131-136, 2011 | 721 | 2011 |
| Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY … JS Healey, J Eikelboom, J Douketis, L Wallentin, J Oldgren, S Yang, ... Circulation 126 (3), 343-348, 2012 | 693 | 2012 |
| Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial AL Dans, SJ Connolly, L Wallentin, S Yang, J Nakamya, M Brueckmann, ... Circulation 127 (5), 634-640, 2013 | 672 | 2013 |
| EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary H Heidbuchel, P Verhamme, M Alings, M Antz, W Hacke, J Oldgren, ... European heart journal 34 (27), 2094-2106, 2013 | 563 | 2013 |
| Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial SH Hohnloser, J Oldgren, S Yang, L Wallentin, M Ezekowitz, P Reilly, ... Circulation 125 (5), 669-676, 2012 | 537 | 2012 |
| The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study Z Hijazi, J Oldgren, J Lindbäck, JH Alexander, SJ Connolly, ... The Lancet 387 (10035), 2302-2311, 2016 | 533 | 2016 |
| Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long … Z Hijazi, SH Hohnloser, J Oldgren, U Andersson, SJ Connolly, ... Circulation 129 (9), 961-970, 2014 | 496 | 2014 |
| Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran MD Ezekowitz, S Connolly, A Parekh, PA Reilly, J Varrone, S Wang, ... American heart journal 157 (5), 805-810. e2, 2009 | 485 | 2009 |
| Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy … Z Hijazi, J Oldgren, U Andersson, SJ Connolly, MD Ezekowitz, ... Circulation 125 (13), 1605-1616, 2012 | 479 | 2012 |
| Variations in cause and management of atrial fibrillation in a prospective registry of 15 400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry J Oldgren, JS Healey, M Ezekowitz, P Commerford, A Avezum, P Pais, ... Circulation 129 (15), 1568-1576, 2014 | 457 | 2014 |
